Faculty and Research: Mentor Program
For the past twenty-four years we have offered a Mentor Program to our students. The purpose of this Program is to provide you and a small group of your colleagues with the opportunity to personally discuss any topic of mutual interest with a leading locally-based, nationally recognized health care executive. (Please see mentor list below). To diversify their experience, students choose a different mentor for their second year. Mentor resumes and proposed meeting dates (if any) for each mentor will be available to help your selection. We will distribute the Mentor Lottery Selection forms during the week of September 4, 2008. We are sure that you will find it to be one of the most rewarding educational experiences you will have at Kellogg.
Maneesh Arora is the senior vice president and chief financial officer of Exact Sciences. Prior to joining Exact, Maneesh served as chief financial officer of Third Wave Technologies, a molecular diagnostic company focused on cervical cancer screening, from January 2006 until the company’s acquisition by Hologic in July 2008. He joined Third Wave in January 2003 as director of strategy and was promoted successively to vice president and senior vice president in 2004. Prior to joining Third Wave, Arora was director of corporate strategy for Nalco Chemical Company. He began his career at Kraft Foods as a financial analyst and held several positions of increasing responsibility during his nine years there. Arora earned a bachelor's degree in economics from the University of Chicago and a master of business administration degree from the Kellogg Graduate School of Management.
Michael Burke (Kellogg ’94) is private company healthcare investor with a focus on specialty pharmaceuticals and molecular diagnostics. He is currently the Chairman of the Board of SureGene LLC, a molecular diagnostic and pharmaceutical company, member of the board of directors of Marathon LLC, a specialty pharmaceutical company and Putney, a veterinary pharmaceutical company. Prior to his current activities, Mr. Burke was one of Ovation Pharmaceuticals founding executives growing the company from start-up to over $200 million in yearly sales and 250+ employees. At Ovation, he was responsible for commercial activities including sales, marketing, partnerships and product acquisitions. In March of 2009, Ovation was sold to H. Lundbeck A/S a publicly traded Danish pharmaceutical company in an all cash transaction valuing Ovation at USD 900 million. Past positions include serving as Chief Commercial Officer and Vice President of Sales and Marketing at Lundbeck Inc. and Ovation Pharmaceuticals, Inc.. Nine years at Abbott Laboratories' Pharmaceutical Products Division in various sales and marketing roles including; Director of the Neuroscience Business Unit responsible for the Depakote® and Depakote® ER neurology and psychiatry business, Senior Product Manager responsible for the Biaxin® respiratory antibiotic business, Product Manager responsible for the Hytrin® cardiovascular and urology business, Managed Healthcare Assistant Product Manager, Sales Representative and Marketing Research Analyst. Before attending Kellogg, Mr. Burke was the founder and President of Athwell, a health promotion consulting service company.
Arthur Holden (Kellogg '81)is the Founder and Chairman of the Pharmaceutical Biomedical Research Consortium [PBRC]. The PBRC is a 501 C3, which serves to advance the field of medicine through the development and implementation of high quality “pre-competitive” biomedical research consortia, across the pharmaceutical industry and academia. The Consortium currently has a major program international effort underway focused on the pharmacogenetics of serious adverse drug reactions [i.e. International Serious Adverse Event Consortium]. Resulting data and outputs from these efforts are being made available to all qualified researchers, free of IP constraints. Until October 2007, Mr. Holden concurrently held the position of Senior Vice President of Corporate and Market Development at Illumina, a leading provider of analytical systems and service for the analysis of genetic variation. It was named the NASDAQ’s fastest growing technology company in 2006 and 2008. In 2000, he was the principal founder of First Genetic Trust, a venture capital [Venrock] backed development stage biotechnology/informatics firm. He served as the company’s Chairman and CEO from 2000-2006. First Genetic Trust develops secure web-based applications to support the acquisition, storage, management, and analysis of genetic and medical data in drug discovery, development and clinical practice. The company was sold in the spring of 2006 to Cerner, Inc. Mr. Holden also served as Chairman of the SNP Consortium. Before serving as Chairman of the SNP Consortium, Mr. Holden was CEO of The SNP Consortium Ltd. which was a nonprofit entity dedicated to creating a high quality, high-density single nucleotide polymorphism (SNP) map of the human genome. Prior to his leadership role with the SNP Consortium Ltd., he was CEO and a Director of Celsis International PLC, an international biotechnology company. He spent the majority of his career as an executive with Baxter International. Mr. Holden serves on a number of non-profit boards. He is Chairman of the Advisory Board for the Biotechnology Management Program at the J.L. Kellogg Graduate School of Management. He is a director of iBIO, the Chicago Children’s Hospital Research Institute, and the Illinois Technology Development Alliance. Mr. Holden has won numerous leadership awards, including being a recipient of the Laura Jackson Achievement Award for outstanding leadership in the healthcare industry from Northwestern University.
John Larson serves as General Manger for Abbott Neuroscience. Mr. Larson joined Abbott in 1999 as a Marketing Manager in the Hospital Products Division. As Marketing Manager, he was responsible for the Abbott's new product development of an acute heart failure drug, the acquisition and re-launch of a successful cardiovascular drug and the management of several on-market hospital products. In 2003, he joined the Global Licensing and New Business Development Group as Director of Acquisitions and Strategic Analysis. Mr. Larson has responsible for Global Licensing's acquisition and joint venture/partnership analyses, licensing and business development activities, strategic planning projects on pharmaceutical initiatives, competitive intelligence, and additional community outreach activities. Prior to rejoining Abbott, he was an Associate Director at Searle, where he held marketing and strategy positions including positions in their Cardiovascular Franchise and Corporate Strategic Planning. Prior to joining Searle, he spent three years in Health care consulting at Coppers & Lybrand focusing on corporate finance and development of new managed care organizations. Previous to this experience, Mr. Larson held positions with Chase Manhattan Bank and Kidder Peabody in variety of commercial and investment banking roles. He serves as a Member at Large at Illinois Biotechnology Industry Organization. Mr. Larson earned a bachelor's degree in English and Political Science from Wesleyan University and master's degree in business administration from the Kellogg School of Management at Northwestern.
David Loucks is President and Chief Executive of Healthios, Inc. (“Healthios”), a healthcare merchant banking firm. Throughout his professional career, Mr. Loucks has been active as an advisor, investor, and general manager across the global healthcare industry, in the process nurturing a unique perspective on the sources of success and the nature of value creation. Healthios was founded in 2005 by Mr. Loucks, following several years spent as Managing Partner of the Aethena Group, LLC, which is a private equity partnership with a broad portfolio of investment interests. During his tenure with Aethena, Mr. Loucks positioned that firm to become one of the most active investors in the global healthcare industry, having participated in more than (40) transactions from 2001 through 2004, representing aggregate enterprise values in excess of $5 billion. Prior to founding the Aethena, from 1998 until 2000, Mr. Loucks served as President and CEO of Physician Dynamics, Inc. (“PDI”), a fully-integrated provider of patient education and disease management solutions for patients afflicted with chronic and acute diseases. Services comprising patient & family education, compliance management, utilization review, outcomes measurement, informed consent, and remote monitoring were sold to hospitals, health plans, and providers throughout the U.S. Among his duties at Robertson Stephens, Mr. Loucks was a founder of the Special Situations practice and he directed that firm’s first international financing initiatives for companies based in Europe, Israel, India, and China. Schooled in Europe, and later a graduate of the Lawrenceville School, of Yale University, and of the Kellogg Graduate School of Management at Northwestern University, Mr. Loucks is multi-lingual and has spent more than 15 years living and working internationally.
Pete Masloski is a Principal with ZS Associates in Evanston, Illinois, and is currently the leader of ZS’ Medical Products and Services Practice. His experience at ZS includes helping clients improve the effectiveness of their marketing and sales efforts in a broad range of areas. Pete’s practice area expertise spans a broad scope from market strategy; such as opportunity assessment, product strategy, organization design, and go-to-market strategy; to organizational effectiveness drivers, such as incentive compensation, targeting and account planning. His clients at ZS have been primarily in the medical devices and medical diagnostics industries. Pete has authored several articles and white papers on topics such as medical device industry trends and their implications, go-to-market strategy, sales effectiveness and incentive compensation. Pete is also currently a member of the sales and distribution advisory board for MX magazine. Pete joined ZS Associates in 1996. Prior to joining ZS Pete worked for The Dow Chemical Company in various research and development and commercial roles. Pete has a Master of Management with distinction from the Kellogg School of Management at Northwestern University. Pete also holds a BSE in Chemical Engineering from Princeton University.
Mr. Terence Mieling has 34 years of healthcare experience with the last 27 in public finance investment banking. From the Chicago office, he is responsible for providing investment banking services to a variety of healthcare clients throughout the country. His clients include Hospital Sisters Health System (WI, IL), Sisters of St. Francis Health Services (IN, IL), Avera Health (SD), MultiCare Health System (WA), Munson Healthcare (MI) and the University of Wisconsin Medical Foundation (WI). Prior to joining Merrill Lynch in 1997, he was National Director for the investment banking firm of John Nuveen & Co. for 17 years. From 1975 through 1980, Mr. Mieling was a Senior Manager with Ernst & Young in Chicago, where he provided consulting services to the health care industries. Prior to Ernst & Young he was a Chief Financial Officer for a hospital in the Hospital Sisters Health System, Springfield, Illinois. Mr. Mieling received his B.S. in Biochemistry from the University of Illinois at Urbana in 1971 and his M.B.A. from the same institution in 1973. In addition, he has been a Certified Public Accountant since 1975.
J.P Gallagher, FACHE is President of Evanston Hospital, the flagship teaching hospital of NorthShore University HealthSystem (NorthShore). Evanston Hospital is a 420 bed Level 1 trauma center with a full range of surgical and medical specialty services. It is also the primary teaching hospital for the four hospital system that serves communities in northern Chicago and the north shore region. Mr. Gallagher joined NorthShore in 2002 as Vice President of Operations at Glenbrook Hospital in Glenview. He has served in a variety of administrative capacities during his tenure with NorthShore including support of several joint-ventures and NorthShore’s academic affiliation with the University of Chicago’s Pritzker School of Medicine. Prior to joining NorthShore, Mr. Gallagher worked for the Advocate Health Care system at Advocate Christ Medical Center in Oak Lawn. His Director responsibilities included support of all inpatient surgical and adult outpatient services. Mr. Gallagher began his career in health care as an Analyst at the Lewin Group, a healthcare consulting firm in Washington, D.C. Mr. Gallagher received his MBA from the Wharton School at the University of Pennsylvania and holds a BA from Princeton University. He and his wife Krista live in Chicago with their three children.
Olivier Visa is director of Pharma marketing at Baxter. He is a seasoned executive in the pharmaceutical industry with global expertise and responsibilities in both strategic and operational marketing. He’s developed a strong acumen of the industry challenges and opportunities throughout his engagement in Drug Delivery. He’s recognized for his focus on growth and investment through customer-centered business strategy and ruthless execution. Olivier has acquired a diverse cultural understanding through all the countries he worked in: UK, Belgium, Germany, Italy, Spain, France, US and Canada. Additionally, his global responsibilities led him to build business relationships with Japan, China, Australia, New Zealand, Latin America and Eastern Europe. He is a Kellogg alum (EMP61, 2005). Being a Board Member and Chairman for fund-raising at the French American Chamber of Commerce based in Chicago drives him to play a significant role in the economic relationships between the US and France, his native country.